MiniMed Group, Inc.MMED

MiniMed Group’s latest 10-K reads like a cautionary tale wrapped in a medical miracle: $3.10 billion in revenue, but a net loss of $333 million. The company’s pitch is slick-CGMs, consumables, software, and services-but the cash math is less so. Operating cash flow was $-197 million, and capex clocked in at $223 million, leaving the balance sheet with a modest $298 million in cash. The filing doesn’t sugarcoat it: MiniMed is selling durable, resilient products, but the cash machine isn’t keeping pace.

The MiniMed 780G insulin pump is the star of the show, adjusting insulin delivery every five minutes, 24/7, with no finger pricks required. It’s the kind of tech that makes diabetics sigh in relief and investors sigh in despair. The system’s algorithms and devices are protected by a patent portfolio focused on features like the MiniMed 780G, Simplera CGM, InPen, and software. The filing notes that 82% of revenue in fiscal 2026 came from these products, which is the good news. The bad news is that diluted EPS is $-1.30, and the company issued 256.6 million shares to fund its operations.

A closer look at the numbers shows MiniMed’s assets at $4.63 billion versus liabilities of $1.02 billion, leaving $3.61 billion in stockholders’ equity. Inventory sits at $341 million, up $29 million from the prior period, and warranty accruals increased by $46 million. The company’s cash and cash equivalents were $298 million, but net cash used in operating activities was $-197 million. The filing is a masterclass in contrasts: impressive tech, but a balance sheet that’s still finding its footing.

The company’s product line includes the MiniMed Go system, a diabetes management platform combining the InPen smart insulin pen, a compatible CGM, and the MiniMed Go mobile app. The MiniMed 780G system is the flagship, offering automatic insulin adjustments every five minutes, 24/7, no finger pricks required. MiniMed’s official product and news rails highlight these offerings, but the financials suggest the company is still paying the piper for its growth.

For a deeper dive into MiniMed’s operations, the SEC EDGAR filing index and company facts JSON provide granular data, while the official product pages and newsroom offer a window into the company’s current offerings. The tension here isn’t the tech-it’s whether the cash math can catch up.